Telix Pharmaceuticals Limited (TLX) Fair Value & Analysis

Healthcare · US · Market cap $3.6B

Below-average quality, and screening another 91% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case ($1.63). The favourable scenario is already priced in.
• Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The model range is unusually wide ($0.4000 to $1.63). The outcome hinges heavily on assumptions, so read the point estimate with caution.

Price vs Fair Value (21 months)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.

How to read this chart

21‑month range $6.41 – $20.93 · fair‑value band $0.4000 – $1.63 · the $10.64 price screens above the $1.01 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 19, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Telix Pharmaceuticals Limited (TLX) currently trades at $10.64, while our model-based Fair Value estimate is $1.01, implying the stock looks roughly 90.5% overvalued today. We read business quality at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Telix Pharmaceuticals Limited generated revenue of $804M at a net margin of -0.9%. Revenue grew 49.3% year over year. It earns a return on equity of -1.9%. Net debt stands at $487M. Fundamentals as of Jul 19, 2026

Our scenario range runs from $0.4000 (bear case) to $1.63 (bull case); at $10.64, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 37% below its 52-week high and 69% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -91%, TLX screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Dividend Discount ($2.45) versus Earnings-Based ($0.2100). Highest evidence: ROIC Compounder (72).

Key figures & financial health

Quality Score breakdown

About the company

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.

Full company description

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Telix Pharmaceuticals Limited reported revenue of $1.2B in FY2025 versus $7.6M in FY2021, a compound +254.9%/yr. Reported net income was −$10.7M in FY2025.

TLX screens 91% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Recent news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

• Telix H1 2026 Results: Investor Webcast Notification Yahoo Finance · Jul 30, 2026
• Why Regeneron (REGN) Is Up 6.7% After Mixed Q2 Results And New Telix Oncology Deal Yahoo Finance · Jul 30, 2026
• Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17% as Wall Street Analysts Expect? Yahoo Finance · Jul 22, 2026
• Telix Pharma Q2 Revenue Rises 21%; Doses First Patient In Phase 3 LUTEON Trial; Shares Jump Nasdaq · Jul 21, 2026

Peer Group

Biotechnology · 606 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Biotechnology median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.